Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Capital Expenditures (2022 - 2025)

Historic Capital Expenditures for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to $27000.0.

  • Phathom Pharmaceuticals' Capital Expenditures fell 3863.64% to $27000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $147000.0, marking a year-over-year decrease of 7570.25%. This contributed to the annual value of $135000.0 for FY2024, which is 9173.81% down from last year.
  • As of Q3 2025, Phathom Pharmaceuticals' Capital Expenditures stood at $27000.0, which was down 3863.64% from $71000.0 recorded in Q2 2025.
  • Phathom Pharmaceuticals' Capital Expenditures' 5-year high stood at $939000.0 during Q3 2023, with a 5-year trough of $5000.0 in Q4 2024.
  • Moreover, its 4-year median value for Capital Expenditures was $71000.0 (2025), whereas its average is $196800.0.
  • Over the last 5 years, Phathom Pharmaceuticals' Capital Expenditures had its largest YoY gain of 66666.67% in 2024, and its largest YoY loss of 9894.74% in 2024.
  • Quarter analysis of 4 years shows Phathom Pharmaceuticals' Capital Expenditures stood at $412000.0 in 2022, then grew by 15.29% to $475000.0 in 2023, then plummeted by 98.95% to $5000.0 in 2024, then soared by 440.0% to $27000.0 in 2025.
  • Its Capital Expenditures stands at $27000.0 for Q3 2025, versus $71000.0 for Q2 2025 and $44000.0 for Q1 2025.